| Literature DB >> 32823389 |
S R Rathinam1, Ilknur Tugal-Tutkun2, Mamta Agarwal3, Vedhanayaki Rajesh1, Merih Egriparmak2, Gazal Patnaik3.
Abstract
Uveitis is a complex disorder including both infectious and non-infectious etiologies. Clinical diagnosis is a challenge because many diseases share common clinical signs. Laboratory support is crucial for confirming the clinical diagnosis. Laboratory diagnosis includes direct tests and indirect tests. For example smear, culture, and molecular diagnostics demonstrate the pathogens, hence they are direct tests. Immunologic tests employ an antigen to detect presence of antibodies to a pathogen, or an antibody to detect the presence of an antigen, of the pathogen in the specimens. The immunological tests used in laboratories are made by producing artificial antibodies that exactly "match" the pathogen in question. When these antibodies come into contact with a sample they bind to the matching pathogen if found in the sample. Hence they are grouped under indirect evidence. There are several investigations in uveitis to reach the confirmed diagnosis including microbiological, immunological, imaging and molecular diagnostic testing. In this section we will discuss immunological investigations of infectious and non-infectious uveitis.Entities:
Keywords: Infectious; investigations; non-infectious; novel infections; uveitis
Mesh:
Substances:
Year: 2020 PMID: 32823389 PMCID: PMC7690523 DOI: 10.4103/ijo.IJO_570_20
Source DB: PubMed Journal: Indian J Ophthalmol ISSN: 0301-4738 Impact factor: 1.848
Immunological tests in uveitis
| Uveitic entity | Disease type | Immunological tests |
|---|---|---|
| Infectious Uveitis | ||
| Bacterial disease | Tuberculosis | Mantoux Test, |
| Interferon-gamma release Assay (IGRA) 6 | ||
| QuantiFeron-Gold In-Tube & T-SPOT TB | ||
| Leprosy | Lepromin test | |
| Syphilis | Treponemal tests | |
| Non Treponemal tests | ||
| Leptospirosis | Microagglutination test, ELISA | |
| Lyme disease | ELISA | |
| Rickettsiae | ELISA Weil Felix test, | |
| Viral diseases | HIV | ELISA. Westren Blot |
| Dengue | ELISA, Plaque Reduction Neutralization test (PRNT) | |
| Chikungunya | ELISA, (PRNT) | |
| West Nile virus | ELISA, RT PCR | |
| Parasitic diseases | Toxoplasmosis | ELISA |
| Toxocariasis | ELISA | |
| Non-infectious Uveitis | ||
| Collagen vascular disease | Rheumatological disorders | |
| Juvenile idiopathic arthritis Systemic lupus erythematosus | Antinuclear Antibody: | |
| Systemic lupus erythematosus | dsDNA, ssDNA (double- and single-stranded deoxyribonucleic acid,) | |
| Scleroderma | Anticentromere antibody, Sm | |
| Rheumatoid arthritis | Rheumatoid Factor: | |
| Anti-Cyclic Citrullinated Peptide: | ||
| Wegener’s granulomatosis | Antineutrophil Cytoplasmic Antibody: C ANCA, | |
| Polyarteritis nodosa (PAN) group | P ANCA, |
Figure 1Figure shows both in vivo (TST test) and in vitro (IGRAs) release of inflammatory cytokines by T-cells sensitized to mycobacterial antigens. In the skin test, antigens are injected intra dermally which bring specific lymphocytes to the site causing release of cytokines resulting in induration. In the blood test, mononuclear cells from peripheral blood produce IFN-γ from sensitized T-cells which is measured by ELISA.[6] Adapted from: Andersen P, Munk ME, Pollock JM, et al. Specific immune- based diagnosis of tuberculosis. Lancet 2000;356:1099-04
Pros and Cons of TST and IGRA
| TST | IGRA |
|---|---|
| Measures skin induration after PPD injection | Detection of IFN-γ |
| Affected by BCG vaccination and other mycobacteria | Unaffected by BCG vaccination and other mycobacteria |
| Less sensitive and specific | More sensitive and specific |
| Cheaper/easy availability | costlier |
| Need for review within 48-72 h | Sample handling difficult |
Figure 2Depicts the steps in Enzye Immuno Assay
Figure 3Depicts the steps in Western Blot
HLA associations of selected uveitis entities
| Uveitis entity | HLA antigen | Frequency (%) |
|---|---|---|
| Birdshot chorioretinopathy | A29 | 96-100 |
| Acute anterior uveitis | B27 | 40-82 |
| Ankylosing spondylitis | B27 | 92 |
| Behçet disease | B51 | 59 |
| Vogt-Koyanagi-Harada disease | DQ4 | 83 |
| DQA1*0301 | Up-100% | |
| DR4 | 93 | |
| DRB1*0405 | Up to 95% | |
| Intermediate uveitis | DR15 | 47-72 |
| Multiple sclerosis | DRB1*1501 | Up-62 |
| Tubulointerstitial nephritis and uveitis | DQA1*01/ | 72 |
| DQB1*05/DRB1*01 |